

---

## Subject Index

- abortion 175, 186, 187, 189, 190
- ACC *see* Acetyl-CoA carboxylase
- acetyl-CoA carboxylase, cytosolic 259, 260
- acetyl-CoA carboxylase, plastid 259, 260, 265
- adhesion 175, 177
- agglutination 175, 177
- ALAD *see* porphobilinogen synthase
- amino acids 276
- aminopeptidases 278, 285
- anemia 85, 88, 95, 171, 173, 175, 181–183, 185, 186
- anti-adhesion 170, 179, 180, 183, 184
- antimalarial, commonly used 258, 262
  - artemisinin 263
  - atovaquone 257, 262
  - proguanil 263
  - quinine 255, 257, 263
- antipyretics, use of 85
- apical membrane antigen-1 (AMA-1) 425, 426
- artemisinins 17, 342
  - alkylation of haem 22
  - artemether 25
  - carbon-centred radical 18
  - falcipain 2 24
  - hydroxyl radical 20
  - mechanism of activation 18
  - membrane damage 21
  - ozonides 27
  - PfATPase6 20, 24, 25
  - target(s) 20
  - TCTP 22
- ascaris infection 94
- aspartic proteases 277, 278
- atopic skin reaction 97
- atovaquone 240, 245, 246
- ATP synthase, F<sub>1</sub>F<sub>0</sub> 236, 237, 241–243
- bacterial infections, secondary 94
  - non-typhoidal salmonellosis 94
  - typhoidal salmonella spp. bacteraemia 94
- carrier, mitochondria 246
- CD36 175, 176
- cellular immune responses 180
- channels 331–333, 335, 337, 338
- chemokines 183, 184
- chondroitin sulfate A (CSA) 175–180, 184
- circumsporozoite protein (CSP) 425–427, 431
- citrate synthase 239
- citric acid cycle *see* tricarboxylic acid cycle
- clinical trials 255–257, 262, 263
  - Africa 255, 262, 263
  - India 255
  - phase II 258, 262
  - Thailand 255, 262
- 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF) 262, 266
- combination, drug 255, 257, 258, 262, 263

- complications 89  
 congenital malaria 181  
 congenital malformation 187, 190  
*Cryptosporidium parvum* 234, 259, 260  
 crystal structure 256, 259, 261  
 CSA-binding parasite 178–180, 184  
 CSA-binding protein 178  
 cysteine proteases 277, 282  
 cytochrome *bc*<sub>1</sub> complex *see*  
   ubiquinol-cytochrome *c*  
   oxidoreductase  
 cytochrome *c* 240  
 cytochrome *c* oxidase 237, 240, 241  
 cytokines  
   – IFN- $\gamma$  180, 181, 183  
   – IL-2 183  
   – IL-8 181, 183  
   – TNF- $\alpha$  181, 183  
   – Type 2 182  
 cystostome 277  
  
 delayed death 257  
 1-deoxy-D-xylulose 5-phosphate  
   reductoisomerase (DOXP  
   reductoisomerase, IspC) 254,  
   262, 266  
 design, inhibitor 259, 261  
 digestive vacuole 334  
 digitonin 328  
 dihydroorotate dehydrogenase 240,  
   241, 245  
 dipeptidyl peptidase 285  
 divalent metal-ion transporters  
   296, 310  
 DNA  
   – mitochondrial 234–236,  
   242–244  
   – plastid 234  
   – polymerase, mitochondrial 244  
 DNA gyrase, plastid 254, 255, 264  
 DNA metabolism, plastid 254, 255,  
   262, 263  
 DNA replication, plastid *see* DNA  
   metabolism, plastid  
 DOXP *see* 1-deoxy-D-xylulose  
   5-phosphate reductoisomerase  
  
 drug target, antimalarial 234, 245  
 drugs  
   – amodiaquine 189  
   – artemisinin derivatives 186–190  
   – atovaquone/proguanil 188–190  
   – chemoprophylaxis 184  
   – chloroquine 185, 187, 188  
   – clindamycin 187, 189, 190  
   – dapsone-chlorproguanil  
   (LapDap<sup>TM</sup>) 190  
   – halofantrine 189  
   – intermittent presumptive  
   treatment (IPT) 184–186  
   – mefloquine 187–190  
   – prophylaxis 170  
   – pyrimethamine/dapsone  
   185, 188  
   – quinine 186–190  
   – safety 170, 187, 189  
   – sulfadoxine-pyrimethamine (SP)  
   186–188  
   – tetracycline 189  
  
 ECG changes 93  
 EF1A *see* elongation factor 1A  
 EF-G *see* elongation factor G  
*Eimeria tenella* 260  
 elderly patients 89–91  
 electron transport chain 235, 236,  
   239–242, 245  
 elongation factor 1A (EF1A), plastid  
   256, 257  
 elongation factor G (EF-G),  
   plastid 258  
 enoyl-ACP reductase 260  
 ENR *see* enoyl-ACP reductase  
 epidemiology  
   – epidemic 171–173  
   – malaria transmission 171–174  
   – multigravid women 181  
   – parity specific 179  
   – primigravid women 183, 185  
 erythrocyte binding-like (EBL)  
   family  
   – BAEBL 422  
   – EBA-175 422, 425

- EBL-1 425
- MAEBL 422, 425, 426
- erythrocytic enzymes for haem biosynthesis 263
- expressed sequence tags (EST) 419, 421, 430
  
- falcilysin 278, 284
  - inhibitors 285
- falcipains 277, 282
  - inhibitors 283
  - profalcipain 286
- FAS I *see* fatty acid synthase, type I
- FAS II *see* fatty acid biosynthesis, type II
- fatty acid biosynthesis, type II (FAS II) 254, 257, 259–261, 265
  - $\beta$ -hydroxyacyl-ACP dehydratase (HAD) 260, 261, 266
  - $\beta$ -ketoacyl-ACP reductase (KAR) 260, 265
  - $\beta$ -ketoacyl-ACP synthase (KAS) 260, 261, 265
  - enoyl-ACP reductase (ENR) 254, 260, 261, 266
- fatty acid synthase, type I (FAS I) 260
- fever 85, 87
- flow cytometry assays 179, 180
  
- gametocytaemia 262
- Gateway technology 424
- gene conversion 243
- genome, mitochondrial
  - absence of tRNA 244
  - gene products 236, 240–242
  - maternal inheritance 235
  - single nucleotide polymorphisms 235
  - smallest 234
- glycolysis, ATP derived from 238
- green fluorescent protein 237, 244
  
- HAD *see*  $\beta$ -hydroxyacyl-ACP dehydratase (HAD)
- haem biosynthesis 238, 245, 254, 263, 266, 310
- haemoglobin 5, 276, 278, 282
  - CQ and AQ 10
  - degradation 5
  - protease enzymes 6
  - transport vesicles 5
- haemozoin 7, 88, 89
  - anemia 297
  - assays 301–306
  - CQ binding 10
  - CQ-FP 11
  - formation 7, 301
  - inhibition by drugs 307
  - inhibition by zinc protoporphyrin 298
  - interference with host metabolism 88
  - mass spectrometric detection 313
  - structure and density 300
- HAP 279
- HEP17 430
- hepatomegaly 92
- herbicide
  - aryloxyphenoxypropionate derivatives 260
  - clodinafop 260
- histidine-rich protein II (HRP II) 301
- HIV-1 94–97, 180, 181
  - associated anaemia 95
  - impact of co-infection 96
  - in pregnancy 95
  - vivax malaria as supportive therapy 97
- HIV-2 96
- HSP-70 430
- hyaluronic acid 177
  
- IgG 177
- IgM 177
- inflammation
  - anti-inflammatory 182
  - cells 175, 182, 184
  - lymphocytes 181
  - monocytes/macrophages 181–183
  - natural killer cells 181

- insect repellents 189  
 insecticide-treated bed nets  
   (ITNs) 189  
 intrauterine growth retardation  
   (IUGR) 174  
 iron  
   – chelation therapy 311  
   – ferritin 309  
   – human metabolism 294–296  
   – malaria changes 296–299  
   – *Plasmodium* metabolism  
     299, 300  
   – transferrin 308  
 iron-sulfur cluster biosynthesis 245  
 isoprenoid biosynthesis 254,  
   262, 266  
 IspC *see* 1-deoxy-D-xylulose  
   5-phosphate reductoisomerase  
 IspF *see* 2C-methyl-D-erythritol-  
   2,4-cyclodiphosphate synthase
- KAR *see*  $\beta$ -ketoacyl-ACP reductase  
 KAS *see*  $\beta$ -ketoacyl-ACP synthase  
 knockout 346  
 Krebs cycle *see* tricarboxylic acid  
   cycle
- laser capture microdissection  
   (LCM) 430  
 liquid chromatography (LC) 421,  
   423, 425, 426  
 low birth weight (LBW) 171,  
   173–175, 180–186
- mass spectrometry 312, 421, 422,  
   425–427, 432  
 maternal death 171–173  
 merozoite surface proteins  
   (MSPs) 422  
 metalloprotease 278, 284  
 microarrays 419–421, 428, 431  
 mitochondrion, *Plasmodium*  
   *falciparum* 253, 256, 263  
   – fluorescent image 253  
 mixed infections 89, 94  
 MR4 424  
 MudPIT 421–424, 426–428
- multi-subunit prokaryotic RNA  
   polymerases (RNAP) 255, 265  
 myocardial damage 93
- NADH dehydrogenase 240, 241  
 neonatal Fc receptor 177  
 neonatal, infant death 171, 172,  
   174, 185, 186  
 new permeability pathways 330  
 non-mevalonate pathway *see*  
   isoprenoid biosynthesis  
 NPP *see* new permeability  
   pathways
- oxidative phosphorylation 238
- parasitophorous vacuole  
   membrane 333  
 parity-specific immunity 178  
 patch-clamp 331  
 PBGS *see* porphobilinogen  
   synthase  
 PDF *see* peptide deformylase  
 peptide deformylase (PDF) 258,  
   259, 265  
   – actinonin 259  
   – N-formyl hydroxamic acid 259  
 permeome 326  
 PfEMP1 (*var* gene) 177–179  
 pigment 182  
 plasma lipid profile 88  
 plasmepsins 277, 278, 280  
   – inhibitors 281, 283  
   – proplasmepsin 280, 286  
 PlasmoDB 432, 433  
*Plasmodium*  
   – *falciparum* 234–236, 238–240,  
     243, 245, 246, 252  
     mitochondrion 263  
   – *knowlesi* 259  
   – malaria parasites 233  
   – *malariae* 174, 175  
   – *ovale* 174  
   – spp. fluorescent image 254  
   – *vivax* 174, 175, 255, 258  
   – *yoelii* 235, 243

- plastid inhibitors, *Plasmodium* spp. 255
- 1,2-dithiole-3-one compounds 261
  - amythiamicin 257
  - aurodox 257
  - azithromycin 258
  - ciprofloxacin 255, 262
  - clindamycin 254, 257, 258, 262, 263
  - cyclic thiopeptides 257
  - cyclothialidines 255
  - doxycycline 258
  - fluoroquinolones 255
  - fosmidomycin 262, 263
  - fusidic acid 258
  - GE2270 257
  - grepafloxacin 255
  - kirromycin 257
  - lincomycin 262
  - micrococcin 258
  - minocycline 256
  - NAS21 261
  - NAS91 261
  - norfloxacin 255
  - novobiocin 255
  - promothiocin A 257
  - pyrazole compounds 261
  - rifampicin 255
  - succinylacetone 263
  - tetracycline 256
  - thiolactomycin (TLM) 260, 261
  - thiostrepton 258
  - triclosan 261, 262
- plastid targeting sequence, *Plasmodium* spp. 252, 259, 260, 263
- PlasmAP 252
- plastid, *Plasmodium* spp. 251
- 35-kb genome 252, 253, 255–257
  - fluorescent image 253
- porphobilinogen synthase (PBGS) 263, 266
- postpartum 180
- premature delivery 174, 175, 186
- prophylactics 258
- protection 181
- protein import, mitochondrial 246
- protein synthesis, plastid 254, 256, 257, 262, 265
- proteolysis 277
- pumps
- Ca<sup>2+</sup> 335, 339, 342
  - H<sup>+</sup> 334–337, 339
- PVM *see* parasitophorous vacuole membrane
- pyrimidine salvage 245
- pyrophosphatase 339
- quinolines 8, 307, 308
- amodiaquine 9
  - chloroquine 8
  - mode of action of CQ 9
  - PfCRT 13
  - Pgh1 14
  - resistance 13
  - structure–activity relationships 15
  - toxicity 15
- RAP complex 426
- recrudescence 262
- renal dysfunction 91, 92
- acute renal failure 91
  - glomerulonephritis 91
  - nephrotic syndrome 91
- replication
- mitochondrial DNA 243
  - rolling circle 243
- resistance, drug 254, 257, 258, 260–262
- RhopH2 426
- ribosomal RNA, fragmented 244
- ribosome, mitochondrial 244
- rifin 177
- rifins 427, 428
- RNA metabolism, plastid 253–255, 265
- RNA polymerase, mitochondrial 244
- RNAi 347, 434
- rosette 175, 177

- 23S rRNA, plastid 257, 258  
 saponin 327, 328  
 sequestration 175  
 severe disease 172  
 side effect, drug 255  
 signs and symptoms, frequency of  
   85, 87  
 sporozoite surface protein  
   (SSP2/TRAP) 424–426,  
   431, 432  
 stillbirth 172, 173, 186, 187,  
   189, 190  
 streptomycin O 327, 328  
 succinate thiokinase *see*  
   succinyl-CoA synthase  
 succinyl-CoA synthase 239  
 syncytiotrophoblast 175, 176  
 syndromes  
   – cerebral malaria 171, 172, 175  
   – placental malaria 170, 180, 182  
   – respiratory distress 171  
  
 targeting, protein  
   – prediction methods 236  
   – to apicoplast 234, 238, 244, 245  
   – to mitochondrion 234, 236, 237,  
   239, 244–246  
 thrombocytopenia 85, 87  
*Toxoplasma gondii* 257–260, 264  
 transaminases 92  
 transcription of mitochondrial DNA  
   243, 244  
  
 transcription, plastid *see* RNA  
   metabolism, plastid  
 translation in mitochondria  
   237, 243  
 transport proteins  
   – PfAQP 337, 341  
   – PfATP4 342  
   – PfATP6 342  
   – PfCRT 337, 340, 342, 344, 345  
   – PfHT 334, 336, 339, 340, 346  
   – PfNT1 337, 339, 341  
   – PfVP1 339  
   – Pgh1 337, 340, 344, 345  
   – V-type H<sup>+</sup>-ATPase 334, 339  
 transporters, mitochondrial 246  
 tricarboxylic acid cycle 237–239  
  
 ubiquinol-cytochrome *c*  
   oxidoreductase 234, 240, 241  
 ubiquinone 240  
  
 vaccine 170  
 var genes (PFEMP1) 427, 428  
 var1CSA 178  
 var2CSA 178, 179  
  
*Xenopus laevis* oocyte 340–343  
  
 yeast 343–345  
 yeast-two-hybrid (Y2H) 423, 424  
  
 zinc protoporphyrin IX 298

# Current Topics in Microbiology and Immunology

Volumes published since 1989 (and still available)

Vol. 250: **Aktorics, Klaus; Wilkins, Tracy, D. (Eds.):** Clostridium difficile. 2000. 20 figs. IX, 143 pp. ISBN 3-540-67291-5

Vol. 251: **Melchers, Fritz (Ed.):** Lymphoid Organogenesis. 2000. 62 figs. XII, 215 pp. ISBN 3-540-67569-8

Vol. 252: **Potter, Michael; Melchers, Fritz (Eds.):** B1 Lymphocytes in B Cell Neoplasia. 2000. XIII, 326 pp. ISBN 3-540-67567-1

Vol. 253: **Gosztanyi, Georg (Ed.):** The Mechanisms of Neuronal Damage in Virus Infections of the Nervous System. 2001. approx. XVI, 270 pp. ISBN 3-540-67617-1

Vol. 254: **Privalsky, Martin L. (Ed.):** Transcriptional Corepressors. 2001. 25 figs. XIV, 190 pp. ISBN 3-540-67569-8

Vol. 255: **Hirai, Kanji (Ed.):** Marek's Disease. 2001. 22 figs. XII, 294 pp. ISBN 3-540-67798-4

Vol. 256: **Schmaljohn, Connie S.; Nichol, Stuart T. (Eds.):** Hantaviruses. 2001. 24 figs. XI, 196 pp. ISBN 3-540-41045-7

Vol. 257: **van der Goot, Gisou (Ed.):** PoreForming Toxins, 2001. 19 figs. IX, 166 pp. ISBN 3-540-41386-3

Vol. 258: **Takada, Kenzo (Ed.):** Epstein-Barr Virus and Human Cancer. 2001. 38 figs. IX, 233 pp. ISBN 3-540-41506-8

Vol. 259: **Hauber, Joachim, Vogt, Peter K. (Eds.):** Nuclear Export of Viral RNAs. 2001. 19 figs. IX, 131 pp. ISBN 3-540-41278-6

Vol. 260: **Burton, Didier R. (Ed.):** Antibodies in Viral Infection. 2001. 51 figs. IX, 309 pp. ISBN 3-540-41611-0

Vol. 261: **Trono, Didier (Ed.):** Lentiviral Vectors. 2002. 32 figs. X, 258 pp. ISBN 3-540-42190-4

Vol. 262: **Oldstone, Michael B.A. (Ed.):** Arenaviruses I. 2002. 30 figs. XVIII, 197 pp. ISBN 3-540-42244-7

Vol. 263: **Oldstone, Michael B. A. (Ed.):** Arenaviruses II. 2002. 49 figs. XVIII, 268 pp. ISBN 3-540-42705-8

Vol. 264/I: **Hacker, Jörg; Kaper, James B. (Eds.):** Pathogenicity Islands and the Evolution of Microbes. 2002. 34 figs. XVIII, 232 pp. ISBN 3-540-42681-7

Vol. 264/II: **Hacker, Jörg; Kaper, James B. (Eds.):** Pathogenicity Islands and the Evolution of Microbes. 2002. 24 figs. XVIII, 228 pp. ISBN 3-540-42682-5

Vol. 265: **Dietzschold, Bernhard; Richt, Jürgen A. (Eds.):** Protective and Pathological Immune Responses in the CNS. 2002. 21 figs. X, 278 pp. ISBN 3-540-42668-X

Vol. 266: **Cooper, Koproski (Eds.):** The Interface Between Innate and Acquired Immunity, 2002. 15 figs. XIV, 116 pp. ISBN 3-540-42894-X

Vol. 267: **Mackenzie, John S.; Barrett, Alan D. T.; Deubel, Vincent (Eds.):** Japanese Encephalitis and West Nile Viruses. 2002. 66 figs. X, 418 pp. ISBN 3-540-42783-X

Vol. 268: **Zwickl, Peter; Baumeister, Wolfgang (Eds.):** The Proteasome-Ubiquitin Protein Degradation Pathway. 2002. 17 figs. X, 213 pp. ISBN 3-540-43096-2

Vol. 269: **Koszinowski, Ulrich H.; Hengel, Hartmut (Eds.):** Viral Proteins Counteracting Host Defenses. 2002. 47 figs. XII, 325 pp. ISBN 3-540-43261-2

Vol. 270: **Beutler, Bruce; Wagner, Hermann (Eds.):** Toll-Like Receptor Family Members and Their Ligands. 2002. 31 figs. X, 192 pp. ISBN 3-540-43560-3

Vol. 271: **Koehler, Theresa M. (Ed.):** Anthrax. 2002. 14 figs. X, 169 pp. ISBN 3-540-43497-6

- Vol. 272: **Doerfler, Walter; Böhm, Petra (Eds.):** Adenoviruses: Model and Vectors in Virus-Host Interactions. Virion and Structure, Viral Replication, Host Cell Interactions. 2003. 63 figs., approx. 280 pp. ISBN 3-540-00154-9
- Vol. 273: **Doerfler, Walter; Böhm, Petra (Eds.):** Adenoviruses: Model and Vectors in Virus-Host Interactions. Immune System, Oncogenesis, Gene Therapy. 2004. 35 figs., approx. 280 pp. ISBN 3-540-06851-1
- Vol. 274: **Workman, Jerry L. (Ed.):** Protein Complexes that Modify Chromatin. 2003. 38 figs., XII, 296 pp. ISBN 3-540-44208-1
- Vol. 275: **Fan, Hung (Ed.):** Jaagsiekte Sheep Retrovirus and Lung Cancer. 2003. 63 figs., XII, 252 pp. ISBN 3-540-44096-3
- Vol. 276: **Steinkasserer, Alexander (Ed.):** Dendritic Cells and Virus Infection. 2003. 24 figs., X, 296 pp. ISBN 3-540-44290-1
- Vol. 277: **Rethwilm, Axel (Ed.):** Foamy Viruses. 2003. 40 figs., X, 214 pp. ISBN 3-540-44388-6
- Vol. 278: **Salomon, Daniel R.; Wilson, Carolyn (Eds.):** Xenotransplantation. 2003. 22 figs., IX, 254 pp. ISBN 3-540-00210-3
- Vol. 279: **Thomas, George; Sabatini, David; Hall, Michael N. (Eds.):** TOR. 2004. 49 figs., X, 364 pp. ISBN 3-540-00534X
- Vol. 280: **Heber-Katz, Ellen (Ed.):** Regeneration: Stem Cells and Beyond. 2004. 42 figs., XII, 194 pp. ISBN 3-540-02238-4
- Vol. 281: **Young, John A. T. (Ed.):** Cellular Factors Involved in Early Steps of Retroviral Replication. 2003. 21 figs., IX, 240 pp. ISBN 3-540-00844-6
- Vol. 282: **Stenmark, Harald (Ed.):** Phosphoinositides in Subcellular Targeting and Enzyme Activation. 2003. 20 figs., X, 210 pp. ISBN 3-540-00950-7
- Vol. 283: **Kawaoka, Yoshihiro (Ed.):** Biology of Negative Strand RNA Viruses: The Power of Reverse Genetics. 2004. 24 figs., IX, 350 pp. ISBN 3-540-40661-1
- Vol. 284: **Harris, David (Ed.):** Mad Cow Disease and Related Spongiform Encephalopathies. 2004. 34 figs., IX, 219 pp. ISBN 3-540-20107-6
- Vol. 285: **Marsh, Mark (Ed.):** Membrane Trafficking in Viral Replication. 2004. 19 figs., IX, 259 pp. ISBN 3-540-21430-5
- Vol. 286: **Madshus, Inger H. (Ed.):** Signalling from Internalized Growth Factor Receptors. 2004. 19 figs., IX, 187 pp. ISBN 3-540-21038-5
- Vol. 287: **Enjuanes, Luis (Ed.):** Coronavirus Replication and Reverse Genetics. 2005. 49 figs., XI, 257 pp. ISBN 3-540-21494-1
- Vol. 288: **Mahy, Brain W. J. (Ed.):** Foot-and-Mouth-Disease Virus. 2005. 16 figs., IX, 178 pp. ISBN 3-540-22419X
- Vol. 289: **Griffin, Diane E. (Ed.):** Role of Apoptosis in Infection. 2005. 40 figs., IX, 294 pp. ISBN 3-540-23006-8
- Vol. 290: **Singh, Harinder; Grosschedl, Rudolf (Eds.):** Molecular Analysis of B Lymphocyte Development and Activation. 2005. 28 figs., XI, 255 pp. ISBN 3-540-23090-4
- Vol. 291: **Boquet, Patrice; Lemichez Emmanuel (Eds.):** Bacterial Virulence Factors and Rho GTPases. 2005. 28 figs., IX, 196 pp. ISBN 3-540-23865-4
- Vol. 292: **Fu, Zhen F (Ed.):** The World of Rhabdoviruses. 2005. 27 figs., X, 210 pp. ISBN 3-540-24011-X
- Vol. 293: **Kyewski, Bruno; Suri-Payer, Elisabeth (Eds.):** CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential. 2005. 22 figs., XII, 332 pp. ISBN 3-540-24444-1
- Vol. 294: **Caligaris-Cappio, Federico, Dalla Favera, Ricardo (Eds.):** Chronic Lymphocytic Leukemia. 2005. 25 figs. VIII, 187 pp. ISBN 3-540-25279-7